ERBB2 and breast carcinoma: As demonstrated by Bai et al., trastuzumab-resistant breast cancer has a downregulated expression of LINC00589 while its expression reduced trastuzumab resistance, multidrug resistance (MDR), and CSC-like characteristics of HER2-positive breast cancer.